Motco Lowers Holdings in Sanofi $SNY

Motco trimmed its holdings in Sanofi (NASDAQ:SNY) by 1.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 69,412 shares of the company’s stock after selling 696 shares during the quarter. Motco’s holdings in Sanofi were worth $3,168,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Jennison Associates LLC boosted its holdings in Sanofi by 10.0% in the second quarter. Jennison Associates LLC now owns 184,873 shares of the company’s stock valued at $8,931,000 after purchasing an additional 16,770 shares during the last quarter. Logan Capital Management Inc. boosted its holdings in Sanofi by 32.4% in the second quarter. Logan Capital Management Inc. now owns 116,215 shares of the company’s stock valued at $5,614,000 after purchasing an additional 28,436 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Sanofi in the second quarter valued at $3,971,000. Transcend Capital Advisors LLC boosted its holdings in Sanofi by 21.6% in the second quarter. Transcend Capital Advisors LLC now owns 4,738 shares of the company’s stock valued at $229,000 after purchasing an additional 843 shares during the last quarter. Finally, Bessemer Group Inc. boosted its holdings in Sanofi by 35.7% in the second quarter. Bessemer Group Inc. now owns 5,890 shares of the company’s stock valued at $285,000 after purchasing an additional 1,551 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on SNY shares. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $56.00 to $58.00 in a report on Monday, September 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday. Finally, Barclays reissued an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Trading Down 0.7%

Shares of Sanofi stock opened at $51.06 on Wednesday. The firm has a market capitalization of $125.38 billion, a PE ratio of 11.96, a P/E/G ratio of 1.41 and a beta of 0.51. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The firm’s 50-day moving average price is $48.70 and its 200 day moving average price is $49.55. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The firm had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. Sanofi’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same period last year, the company posted $2.25 EPS. On average, sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.